From Our Thought Leader's

ICON CEO, Dr. Steve Cutler, Highlights Strong Performance and Affirms 2024 Financial Guidance

ICON plc (NASDAQ:ICLR), a global leader in healthcare intelligence and clinical research,  announced its financial results for the fourth quarter and full year ending December 31, 2023. CEO, Dr. Steve Cutler, remarked, "ICON’s solid perfo... Read more

22 February, 2024 | Thursday | Company results
Bio-Rad's CEO, Norman Schwartz, Anticipates Sector Rebound in 2024 Amid Fourth Quarter Challenges

Bio-Rad Laboratories Inc. reports a 6.7% decrease in fourth-quarter net sales compared to 2022, largely attributed to ongoing weakness in biopharma markets. Life Science segment sales declined by 19.1%, driven by lower sales of key products, while Cl... Read more

16 February, 2024 | Friday | Company results
CEO Ari Bousbib Commends IQVIA's Resilience Amidst Challenging 2023 Landscape

  -IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a global leader in advanced analytics, technology solutions, and clinical research services for the life sciences industry, has announced its financial results for the fourth quarter and ... Read more

15 February, 2024 | Thursday | Company results
GDMC Charts a New Course in Genetic Therapy Innovation with Strategic Series A Investment

In an interview with BioPharma BoardRoom, Eric Blair, GDMC’s Chief Business Officer, discusses the company's strategic use of Series A funding to pioneer advancements in genetic therapies. Blair sheds light on GDMC's plans for capital equipment... Read more

14 February, 2024 | Wednesday | Interview

Bio Finance

Aizon Raises $20M in Series C Funding to Revolutionize Pharma Manufacturing

      Aizon, the AI SaaS provider transforming pharmaceutical manufacturing, announced today the closing of a $20 million Series C funding round led by NewVale Capital. Existing investors Atlantic Bridge, Crosslink C... Read more

09 February, 2024 | Friday | News
Alto's Brainy Bonanza: Neuroscience Powerhouse ANRO Unleashes $128.6M IPO Surge

In a move that adds an intriguing layer to the IPO dynamics, Alto has granted underwriters a 30-day option to scoop up an additional 1,206,000 shares of common stock at the IPO price. This brainy boost aims to elevate the company's financial ascent, ... Read more

02 February, 2024 | Friday | News

Contract Services

Vetter Pioneers Market Launch of Eight Innovative Drug Products in 2023

Vetter, a globally recognized contract development and manufacturing organization (CDMO), proudly announces the successful market introduction of eight customer drug products by the end of 2023. This achievement underscores Vetter's pivotal role in a... Read more

14 February, 2024 | Wednesday | News
Antitrust Showdown Looms Over Novo-Catalent Mega Deal!

  In a bold move, Ricks emphasized the urgency for financial regulators to scrutinize the deal, pointing out Catalent's extensive client base, comprising over a hundred entities set to compete with Novo Nordisk. The battleground is set for a f... Read more

08 February, 2024 | Thursday | News

BioPharma Video

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close